CONRAY 400 Drug Patent Profile
When do Conray 400 patents expire, and when can generic versions of Conray 400 launch?
Conray 400 is a drug marketed by Mallinckrodt and is included in one NDA.
The generic ingredient in CONRAY 400 is iothalamate sodium. There is one drug master file entry for this compound. Additional details are available on the iothalamate sodium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CONRAY 400?
- What are the global sales for CONRAY 400?
- What is Average Wholesale Price for CONRAY 400?
Summary for CONRAY 400
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 20 |
| Patent Applications: | 691 |
| DailyMed Link: | CONRAY 400 at DailyMed |
US Patents and Regulatory Information for CONRAY 400
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt | CONRAY 400 | iothalamate sodium | INJECTABLE;INJECTION | 014295-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
